imipenem, anhydrous has been researched along with Diabetic Feet in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 2 (14.29) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Citron, DM; Fernandez, HT; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, YA | 1 |
| Agoons, BB; Etoga, MCE; Jingi, AM; Mbanya, JC; Mekobe, FM; Ngassam, E; Sobngwi, E; Yefou, MD | 1 |
| Alishahi, M; Arastehfar, A; Davani, F; Khorram, M; Sabzi, M; Zomorodian, K | 1 |
| Chow, I; Einarson, TR; Lemos, EV | 1 |
| Bayram, H; Dalay, C; Dalkiran, A; Saltoglu, N; Sert, M; Tasova, Y; Tetiker, T | 1 |
| Devidze, G; Jibladze, M; Kistauri, A | 1 |
| Al-Ebous, AD; Al-Jahmi, M; Al-Zuriqat, AN; Hiasat, B; Sarayrah, M | 1 |
| Gemignani, G; Leonildi, A; Menichetti, F; Palumbo, F; Piaggesi, A; Tascini, C; Tedeschi, A | 1 |
| Gemignani, G; Lambelet, P; Leonildi, A; Lucarini, A; Menichetti, F; Palumbo, F; Piaggesi, A; Tascini, C; Tedeschi, A | 1 |
| Freeman, DV; Gibbons, GW; Grayson, ML; Habershaw, GM; Karchmer, AW; Levin, E; Pomposelli, FB; Rosenblum, BI | 1 |
| Abbott, TA; Berger, ML; Dasbach, EJ; Hu, XH; Markson, LE | 1 |
| Antsypovich, EA; Brusnitsyna, MA; Kadyshev, IuG; Molchanov, VF | 2 |
| Briskin, BS; Khachatrian, NN; Kuznetsov, EV; Nekrasova, NI; Sosnovikova, OG; Suplotova, AA | 1 |
1 review(s) available for imipenem, anhydrous and Diabetic Feet
| Article | Year |
|---|---|
Management and prevention of diabetic foot ulcers and infections: a health economic review.
Topics: Ampicillin; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Cost-Benefit Analysis; Diabetes Complications; Diabetic Foot; Drug Combinations; Economics, Pharmaceutical; Humans; Imipenem; Quality-Adjusted Life Years; Sulbactam | 2008 |
5 trial(s) available for imipenem, anhydrous and Diabetic Feet
| Article | Year |
|---|---|
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetic Foot; Drug Combinations; Female; Hospitals, University; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2010 |
Management of diabetic foot in a Jordanian hospital.
Topics: Amikacin; Amputation, Surgical; Anti-Bacterial Agents; Ceftazidime; Chemotherapy, Adjuvant; Debridement; Diabetic Foot; Drug Combinations; Drug Monitoring; Humans; Imipenem; Kidney Diseases; Length of Stay; Lincomycin; Metronidazole; Patient Selection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis; Severity of Illness Index; Treatment Outcome; Wound Healing; Wound Infection | 2005 |
Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Colistin; Combined Modality Therapy; Debridement; Diabetic Foot; Drug Resistance, Multiple, Bacterial; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Osteomyelitis; Pseudomonas Infections; Retrospective Studies; Rifampin; Treatment Outcome | 2006 |
Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients.
Topics: Adult; Ampicillin; Amputation, Surgical; Bacterial Infections; Cilastatin; Combined Modality Therapy; Debridement; Diabetic Foot; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Humans; Imipenem; Osteomyelitis; Sulbactam; Treatment Outcome | 1994 |
[Selective intra-arterial use of small doses of thienam and vasaprostanin the treatment of suppurative diseases of the foot in patients with diabetes mellitus].
Topics: Aged; Alprostadil; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetic Foot; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Infusions, Intra-Arterial; Male; Middle Aged; Suppuration; Time Factors; Vasodilator Agents | 1998 |
8 other study(ies) available for imipenem, anhydrous and Diabetic Feet
| Article | Year |
|---|---|
In vitro activities of doripenem and six comparator drugs against 423 aerobic and anaerobic bacterial isolates from infected diabetic foot wounds.
Topics: Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Carbapenems; Diabetic Foot; Doripenem; Humans; Microbial Sensitivity Tests | 2008 |
Bacterial profile of diabetic foot infections and antibiotic susceptibility in a specialized diabetes centre in Cameroon.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Cameroon; Communicable Diseases; Diabetes Mellitus, Type 2; Diabetic Foot; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Imipenem; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies | 2022 |
Dual drug delivery of vancomycin and imipenem/cilastatin by coaxial nanofibers for treatment of diabetic foot ulcer infections.
Topics: Anti-Bacterial Agents; Cilastatin; Diabetes Mellitus; Diabetic Foot; Drug Liberation; Escherichia coli; Humans; Imipenem; Methicillin-Resistant Staphylococcus aureus; Nanofibers; Pharmaceutical Preparations; Staphylococcus aureus; Vancomycin | 2021 |
[The characteristics of various forms of complicated surgery infections of the diabetic foot syndrome and their antibacterial treatment].
Topics: Adult; Aged; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetic Foot; Drug Combinations; Female; Humans; Imipenem; Ischemia; Male; Middle Aged; Wound Infection | 2011 |
Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis.
Topics: Aged; Anti-Bacterial Agents; Colistin; Diabetic Foot; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Follow-Up Studies; Humans; Imipenem; Male; Metatarsal Bones; Osteomyelitis; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin | 2006 |
Antibiotic therapy for foot infections in diabetics.
Topics: Ampicillin; Cilastatin; Cost-Benefit Analysis; Diabetic Foot; Drug Therapy, Combination; Foot Diseases; Humans; Imipenem; Sulbactam | 1997 |
[Selective intraarterial application of Thienam and Vasoprostan in the treatment of purulent foot diseases in patients with diabetes mellitus].
Topics: Abscess; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetes Complications; Diabetic Foot; Drug Combinations; Drug Therapy, Combination; Humans; Imipenem; Microsurgery; Vasodilator Agents | 1998 |
[Experience in the use of imipenem/cilastatin (thienam) in a surgical clinic].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibiotic Prophylaxis; Cilastatin; Cilastatin, Imipenem Drug Combination; Diabetic Foot; Drug Combinations; Female; Humans; Imipenem; Male; Middle Aged; Pancreatitis, Acute Necrotizing; Peritonitis; Postoperative Care; Protease Inhibitors; Suppuration; Thienamycins | 2000 |